ING Groep NV Takes $318,000 Position in Galectin Therapeutics Inc. Common Stock (GALT)

Share on StockTwits

ING Groep NV acquired a new position in Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 50,000 shares of the company’s stock, valued at approximately $318,000. ING Groep NV owned about 0.12% of Galectin Therapeutics Inc. Common Stock as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in GALT. BlackRock Inc. increased its holdings in Galectin Therapeutics Inc. Common Stock by 199.9% in the second quarter. BlackRock Inc. now owns 588,308 shares of the company’s stock worth $3,742,000 after buying an additional 392,151 shares during the last quarter. EAM Global Investors LLC bought a new stake in Galectin Therapeutics Inc. Common Stock during the first quarter worth approximately $1,076,000. Millennium Management LLC bought a new stake in Galectin Therapeutics Inc. Common Stock during the first quarter worth approximately $454,000. Tibra Equities Europe Ltd bought a new stake in Galectin Therapeutics Inc. Common Stock during the first quarter worth approximately $301,000. Finally, Belpointe Asset Management LLC bought a new stake in Galectin Therapeutics Inc. Common Stock during the second quarter worth approximately $277,000. Hedge funds and other institutional investors own 13.60% of the company’s stock.

In other news, Director Gilbert S. Omenn sold 11,000 shares of the stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $6.03, for a total value of $66,330.00. Following the completion of the sale, the director now directly owns 56,561 shares of the company’s stock, valued at $341,062.83. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jack W. Callicutt sold 226,000 shares of the stock in a transaction that occurred on Wednesday, June 20th. The shares were sold at an average price of $8.61, for a total value of $1,945,860.00. Following the completion of the sale, the chief financial officer now directly owns 103,993 shares of the company’s stock, valued at $895,379.73. The disclosure for this sale can be found here. Insiders sold 538,230 shares of company stock valued at $4,411,462 over the last three months. 38.80% of the stock is owned by company insiders.

Galectin Therapeutics Inc. Common Stock stock traded up $0.06 during trading hours on Friday, reaching $5.42. 588,156 shares of the company were exchanged, compared to its average volume of 799,011. Galectin Therapeutics Inc. Common Stock has a 12 month low of $1.28 and a 12 month high of $9.49.

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) last announced its earnings results on Tuesday, August 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). equities analysts predict that Galectin Therapeutics Inc. Common Stock will post -0.44 EPS for the current fiscal year.

GALT has been the subject of a number of recent analyst reports. ValuEngine raised Galectin Therapeutics Inc. Common Stock from a “hold” rating to a “buy” rating in a research report on Friday, June 1st. BidaskClub raised Galectin Therapeutics Inc. Common Stock from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Galectin Therapeutics Inc. Common Stock in a research report on Thursday, August 16th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Galectin Therapeutics Inc. Common Stock presently has a consensus rating of “Buy” and an average price target of $6.94.

Galectin Therapeutics Inc. Common Stock Company Profile

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.

Featured Story: Asset Allocation

Institutional Ownership by Quarter for Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.